Papiliximab

N/A

Report date: 2024/07/11 15:45:53

Base Information

Drug NamePapiliximab

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)

Mechanisms of ActionAnti-Cluster of differentiation 47Anti-Programmed death-ligand 1

TargetsCluster of differentiation 47Programmed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesShaperon

China Registration ClassN/A

Develop Information

Active CompaniesShaperon Seoul National University

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A